Secunderabad Chronicle

Refractory Metastatic Melanoma Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Treatment Domain

 Breaking News
  • No posts were found

Refractory Metastatic Melanoma Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Treatment Domain

December 08
11:04 2022
Refractory Metastatic Melanoma Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Treatment Domain

DelveInsight’s, “Refractory Metastatic Melanoma Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Refractory metastatic melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Refractory Metastatic Melanoma Pipeline Report

  • DelveInsight’s Refractory Metastatic Melanoma Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Refractory Metastatic Melanoma.
  • The leading Refractory Metastatic Melanoma Companies are working includes Idera Pharmaceuticals,  Bristol-Myers Squibb, Sunesin Pharmaceuticals, Taiga biotechnologies, BioNtech, and others.
  • Promising Refractory Metastatic Melanoma Pipeline therapies include rAd.CD40L, Pembrolizumab, Sunitinib, Pixatimod, Nivolumab, Cyclophosphamide (low dose), NY-ESO-1 peptide vaccine, aldesleukin, sargramostim, and others.
  • The Refractory Metastatic Melanoma Companies and academics are working to assess challenges and seek opportunities that could influence Refractory metastatic melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Refractory metastatic melanoma.

 

Recent Developmental Activities in the Refractory Metastatic Melanoma Pipeline

  • Idera Pharmaceuticals’ new drug candidate, IMO-2125, is an intratumoral injection in development for the treatment of refractory metastatic melanoma from staged II b to IV. The drug has demonstrated good efficacy in its phase I and phase II clinical trials. IMO-2125 is a toll-like receptor agonist that signals the immune system to create and activate cancer-fighting cells (T-cells) to target solid tumors in refractory melanoma patients.
  • Bristol’s “breakthrough” drug Linrodostat is an orally administered drug molecule is currently being evaluated for the treatment of refractory metastatic melanoma and has demonstrated good safety and tolerability in Phase I trials. Linrodostat is an inhibitor of indoleamine 2, 3-deoxygenase 1 (IDO1) with potential immunomodulating and antineoplastic activities.

 

Get an overview of the Refractory Metastatic Melanoma Clinical Trials @ Refractory Metastatic Melanoma Pipeline Outlook Report

 

Refractory Metastatic Melanoma Overview

Refractory metastatic melanoma is the neoplasm of the melanocytes (melanin producing cells). Though melanoma is not common but are the most serious type of skin cancer. Melanoma can develop anywhere on the skin, it can also occur in eyes and other parts of body and on very rare occasions in intestine. Metastatic melanoma can invade the lymphatic system and spread. Exact cause of melanoma is still unclear, however the mutation in DNA of melanocyte due to exposure to UV rays, and other environmental factors are likely to be the leading cause for melanomas. Melanomas can affect both sexes equally. Individuals with history of sunburn, weakened immune system, many moles or unusual moles on the body, excessive exposure to the ultraviolet radiations, and family-history of melanoma are more prone to develop metastatic melanoma.

 

Refractory Metastatic Melanoma Pipeline Report

In the Refractory Metastatic Melanoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Metastatic Melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Refractory Metastatic Melanoma Emerging Drugs Profile

  • IMO-2125: Idera Pharmaceuticals
  • Linrodostat: Bristol-Myers Squibb

 

Refractory Metastatic Melanoma Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Refractory metastatic melanoma. The companies which have their Refractory metastatic melanoma drug candidates in the mid to advanced stage, i.e. phase III include, Idera Pharmaceuticals and others.

 

Request a sample and discover the recent advances in Refractory Metastatic Melanoma Treatment Drugs @ Refractory Metastatic Melanoma Ongoing Clinical Trials Analysis

 

Scope of the Refractory Metastatic Melanoma Pipeline Report

  • Coverage- Global
  • Refractory Metastatic Melanoma Companies are working includes Idera Pharmaceuticals,  Bristol-Myers Squibb, Sunesin Pharmaceuticals, Taiga biotechnologies, BioNtech, and others.
  • Refractory Metastatic Melanoma Pipeline therapies include rAd.CD40L, Pembrolizumab, Sunitinib, Pixatimod, Nivolumab, Cyclophosphamide (low dose), NY-ESO-1 peptide vaccine, aldesleukin, sargramostim, and others
  • Refractory Metastatic Melanoma Emerging Drugs, Unmet Needs, Clinical Trials, Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Refractory Metastatic Melanoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Refractory Metastatic Melanoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Refractory Metastatic Melanoma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. IMO-2125: Idera Pharmaceuticals
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Linrodostat: Bristol-Myers Squibb
  14. Drug profiles in the detailed report…..
  15. Pre-clinical and Discovery Stage Products
  16. Drug name: Company name
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Refractory metastatic melanoma Key Companies
  20. Refractory Metastatic Melanoma Key Products
  21. Refractory Metastatic Melanoma- Unmet Needs
  22. Refractory Metastatic Melanoma- Market Drivers and Barriers
  23. Refractory Metastatic Melanoma- Future Perspectives and Conclusion
  24. Refractory Metastatic Melanoma Analyst Views
  25. Refractory Metastatic Melanoma Key Companies
  26. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Refractory metastatic melanoma drugs?
  • How many Refractory metastatic melanoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Refractory metastatic melanoma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Refractory metastatic melanoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Refractory metastatic melanoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Refractory Metastatic Melanoma Pipeline therapeutics, reach out to Refractory Metastatic Melanoma Treatment Landscape

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Related Articles